<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24603" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lymphomatoid Papulosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Toumi</surname>
            <given-names>Asma</given-names>
          </name>
          <aff>Charles Nicolle Hosp of Tunis Un Tunis</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fazal</surname>
            <given-names>Salman</given-names>
          </name>
          <aff>Allegheny Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Litaiem</surname>
            <given-names>Noureddine</given-names>
          </name>
          <aff>University of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Asma Toumi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Salman Fazal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Noureddine Litaiem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24603.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Lymphomatoid papulosis is a non-aggressive T-cell lymphoma characterized by recurrent, spontaneously regressive papulonodular and sometimes, necrotic lesions, often disseminated with histologic features suggestive of a CD30-positive lymphoma. It accounts for about 12% of cutaneous lymphomas. This activity reviews the evaluation and management of lymphomatoid papulosis and highlights the role of the interprofessional team in evaluating and improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the histopathological characteristics of lymphomatoid papulosis.</p></list-item><list-item><p>Summarize the epidemiology of lymphomatoid papulosis.</p></list-item><list-item><p>Describe the treatment options for lymphomatoid papulosis.</p></list-item><list-item><p>Identify interprofessional team strategies for improving care coordination and outcomes in patients with lymphomatoid papulosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24603&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24603">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24603.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Lymphomatoid papulosis is a non-aggressive T-cell lymphoma characterized by recurrent, spontaneously regressive papulonodular and sometimes, necrotic lesions, often disseminated with histologic features suggestive of a CD30-positive lymphoma. It accounts for about 12% of cutaneous lymphomas. It is classified, alongside primary cutaneous anaplastic large cell lymphoma, in the group of T-cell proliferations expressing CD30.<xref ref-type="bibr" rid="article-24603.r1">[1]</xref>&#x000a0;Patients affected with lymphomatoid papulosis are at risk of developing another hematological disorder: mainly mycosis fungoides, erythrodermic T-cell lymphoma, Hodgkin disease, or large-cell CD30+ lymphoma.</p>
      </sec>
      <sec id="article-24603.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology&#x000a0;of&#x000a0;lymphomatoid papulosis is unknown. A viral etiology has been suggested. However, studies searching for an etiologic role for Epstein-Barr virus and other herpesviruses have been consistently negative. The mechanisms involved in the spontaneous regression of skin lesions have not yet been identified. Interactions between CD30 and its ligand (CD30L) may contribute to apoptosis of the neoplastic T cells and the subsequent regression of the skin lesions, but the exact mechanism is as yet unknown.<xref ref-type="bibr" rid="article-24603.r2">[2]</xref></p>
      </sec>
      <sec id="article-24603.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Lymphomatoid papulosis accounts for about 12% of cutaneous lymphomas. It may occur at any age but, on average,&#x000a0;earlier than CD30+ anaplastic large-cell lymphomas. It is less exceptional in children.&#x000a0;In large series, the&#x000a0;mean age of onset varies between 35 and 45 years.&#x000a0;The male-to-female ratio is approximately 1 to 5.</p>
      </sec>
      <sec id="article-24603.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The cutaneous biopsy reveals a dense dermal lymphocyte infiltrate of evocative triangular morphology with an epidermal base seen at low magnification. The composition of the infiltrate is variable and correlates with the age of the lesion. The epidermis is frequently ulcerated. Several histologic types of lymphomatoid papulosis have been described. According to the number of lymphocytes expressing CD30 and according to their size, we distinguish type A papulosis in which the CD30 cells are numerous, type B very&#x000a0;close to the mycosis fungoides with no or few CD30+ cells and epidermotropism, and finally, type C, with large CD30+ lymphocyte plaques. Other rare forms have been reported: forms expressing markers of cytotoxicity, CD8, TIA1, granzyme B,<xref ref-type="bibr" rid="article-24603.r3">[3]</xref>&#x000a0;forms with angiotropism,<xref ref-type="bibr" rid="article-24603.r4">[4]</xref>&#x000a0;and strictly follicular forms mainly affecting the scalp.<xref ref-type="bibr" rid="article-24603.r5">[5]</xref>&#x000a0;Different types, in particular types A and B, can be observed in the same patient, not only from one lesion to another but also within the same lesion. The vital prognosis and the risk of association with a second hemopathy do not seem to vary from one histological form to another.</p>
      </sec>
      <sec id="article-24603.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The classic clinical presentation is characterized by a red-brown papulonodular eruption that may become hemorrhagic and necrotic. These lesions regress within 2 to 12 weeks, leaving hypopigmented, hyperpigmented, or characteristic atrophic (varioliform) scars.<xref ref-type="bibr" rid="article-24603.r1">[1]</xref>&#x000a0;The coexistence of different age elements is common. Recurrence is the rule with complete remissions of variable duration. Mucosal lesions, particularly oral, are possible but exceptional.<xref ref-type="bibr" rid="article-24603.r6">[6]</xref>&#x000a0;The lesions vary in number from one individual to another and from one recurrence to another. Lesions may be localized, sometimes clustered within rather well-defined areas, or generalized. All areas of the skin may be affected with a predilection for the trunk and limbs. The eruption is generally&#x000a0;asymptomatic.</p>
      </sec>
      <sec id="article-24603.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Skin biopsy is required to confirm the diagnosis and exclude other closely mimicking diseases. Histologically A, B, or C subtypes can be identified. Once the diagnosis of lymphomatoid papulosis is confirmed, no complimentary assessments are needed. The blood count in the search for circulating atypical cells is useless. Complete blood count with biochemistry and lactate dehydrogenase are done as baseline tests. The potentially associated hematological diseases being, almost exclusively, cutaneous lymphomas, only attentive clinical examination of the skin is necessary. No imaging studies are indicated unless there is a concern for secondary lymphoma.</p>
      </sec>
      <sec id="article-24603.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>As it is a rare and clinically polymorphic pathology, no controlled prospective therapeutic study could be conducted to validate a certain treatment. The treatments are only suspensive and poorly efficient. In patients with relatively few non-scarring lesions, therapeutic abstention can be considered. Disabling or cosmetically disturbing forms can be attenuated or controlled with weekly doses of 5 to 20 mg of methotrexate. Used orally, subcutaneously, or intramuscularly, methotrexate is the systemic treatment of choice for lymphomatoid papulosis, regardless of histological type.<xref ref-type="bibr" rid="article-24603.r7">[7]</xref><xref ref-type="bibr" rid="article-24603.r8">[8]</xref>&#x000a0;Starting with low doses (7.5 to 10 mg per week) and then increased in increments of 2.5 or 5 mg until remission of the disease is&#x000a0;obtained. Doses higher than 25 mg per week are rarely needed. Once the remission is obtained, the dosage is gradually tapered until the lowest effective dose, or until discontinuation. In their recent publication on their experience with methotrexate in lymphomatoid papulosis, the Dutch cutaneous lymphoma group reported 90% of good to very good results, but less than one-third of patients were able to discontinue treatment following complete and sustainable remission.<xref ref-type="bibr" rid="article-24603.r8">[8]</xref>&#x000a0;Phototherapy can also be offered. Psoralen + ultraviolet A (PUVA) therapy has been proposed for more than 30 years to treat lymphomatoid papulosis. The disappearance of the lesions is often obtained after about fifteen sessions, but recurrences are frequent. The local chemotherapies (solution or gel of mechlorethamine), bexarotene, interferon, are sometimes used as therapeutic alternatives. When larger skin tumors develop in the course of&#x000a0;lymphomatoid papulosis, surgical excision or radiotherapy can be proposed if spontaneous resolution does not occur after a period of&#x000a0;4 to 12 weeks.</p>
        <p>The treatment of the child's papulosis poses difficulties because of the particular&#x000a0;therapeutic risk of phototherapy at this age and the fear of using methotrexate in pediatrics. Most authors recommend therapeutic abstention or the use of very strong topical corticosteroids on papules at the initial inflammatory stages. The risk of scarring of the lesions may lead to general treatment, and ultraviolet B (UVB) phototherapy will be preferred, although its results in children are inconsistent.<xref ref-type="bibr" rid="article-24603.r9">[9]</xref></p>
        <p>Because of the potential risk for developing a systemic lymphoma, long-term follow-up is required in all patients with lymphomatoid papulosis.</p>
      </sec>
      <sec id="article-24603.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The chronic nature of the disease and spontaneous regression of each elementary lesion leaving a scar, are so characteristic of lymphomatoid papulosis that differential diagnoses are rarely raised. However, the pauci-lesional form is frequently misinterpreted as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Insect bites</p>
          </list-item>
          <list-item>
            <p>Prurigo</p>
          </list-item>
          <list-item>
            <p>Lichenoid pityriasis</p>
          </list-item>
          <list-item>
            <p>Folliculitis</p>
          </list-item>
          <list-item>
            <p>Scabies</p>
          </list-item>
        </list>
        <p>Histologically, the distinction may be impossible between lymphomatoid papulosis type B and mycosis fungoides, or between lymphomatoid papulosis type C and CD30 anaplastic large cell lymphoma. The diagnosis is then based on the anatomoclinical confrontation privileging the clinical aspect. The distinction between mycosis fungoides of early-stage associated with lymphomatoid papulosis (good prognosis) and a transformed mycosis fungoides of nodular evolution (poor prognosis) is important and sometimes difficult. It is based on anamnesis and anatomoclinical expertise.</p>
      </sec>
      <sec id="article-24603.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients affected with lymphomatoid papulosis are at risk of developing another hematological disorder, mainly mycosis fungoides, erythrodermic T-cell lymphoma, Hodgkin disease, or large-cell CD30+ lymphoma. The hematological malignancy may precede, follow, or be concomitant with the appearance of lymphomatoid papulosis. This risk varies from 2% to 15% after 5 years of evolution, but it increases with the duration of&#x000a0;the disease. Older age and especially the presence of a T-cell clone in the papulosis lesions are significant risk factors for the occurrence of a second haemopathy.<xref ref-type="bibr" rid="article-24603.r10">[10]</xref>&#x000a0;The impact on the quality of life can be important, because of the chronic&#x000a0;course of the disease and the possible&#x000a0;localization in visible skin areas. Regardless of the risk of secondary disease, the prognosis of lymphomatous papulosis is excellent with&#x000a0;a 10-year disease-specific survival of almost 100%.<xref ref-type="bibr" rid="article-24603.r11">[11]</xref></p>
      </sec>
      <sec id="article-24603.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Lymphomatoid papulosis patients are at an increased risk of developing secondary malignancies and these include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Erythrodermic T cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Hodgkin disease</p>
          </list-item>
          <list-item>
            <p>Large cell CD30+ lymphoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24603.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be instructed that they are not infectious to others. Local wound care should be taught to every patient. Wound/lesion should be cleaned with soap and water two times a day, to prevent infection topical petroleum ointment should be applied. Crusted lesions must be covered with a loose bandage. Patients are instructed to report if they develop any of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin nodules or lesions that do not regress over three months</p>
          </list-item>
          <list-item>
            <p>Enlarged lymph nodes in the neck, axillae, or groin</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
        </list>
        <p>The above sign and symptoms may herald the onset of infection or associated malignancy.</p>
      </sec>
      <sec id="article-24603.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients affected with lymphomatoid papulosis are at risk of developing another hematological disorder in 5% to 20% of the cases, mainly mycosis fungoides, erythrodermic T-cell lymphoma, Hodgkin's disease, or large-cell CD30+ lymphoma. Therefore, cooperation between dermatologists and hematologist-oncologists is necessary to improve patient-centered care.</p>
        <p>Furthermore, histologically, the distinction may be impossible between lymphomatoid papulosis type B and mycosis fungoides or between lymphomatoid papulosis type C and CD30 anaplastic large cell lymphoma. Without a proper history, the pathologist may be misled. Therefore, the diagnosis should be based on the anatomo-clinical confrontation privileging the clinical aspect.</p>
      </sec>
      <sec id="article-24603.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24603&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24603">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/lymphomatoid-papulosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24603">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24603/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24603">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24603.s15">
        <title>References</title>
        <ref id="article-24603.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cerroni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ralfkiaer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chimenti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Diaz-Perez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Duncan</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kerl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurrer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knobler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sterry</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whittaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>WHO-EORTC classification for cutaneous lymphomas.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>May</month>
            <day>15</day>
            <volume>105</volume>
            <issue>10</issue>
            <fpage>3768</fpage>
            <page-range>3768-85</page-range>
            <pub-id pub-id-type="pmid">15692063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manuelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pimpinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mavilia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maggi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cappugi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giannotti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kadin</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression.</article-title>
            <source>Blood</source>
            <year>1999</year>
            <month>Nov</month>
            <day>01</day>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>3077</fpage>
            <page-range>3077-83</page-range>
            <pub-id pub-id-type="pmid">10556192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertolotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pham-Ledard</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Vergier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parrens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lymphomatoid papulosis type D: an aggressive histology for an indolent disease.</article-title>
            <source>Br J Dermatol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>169</volume>
            <issue>5</issue>
            <fpage>1157</fpage>
            <page-range>1157-9</page-range>
            <pub-id pub-id-type="pmid">23746266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kazakov</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;rer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>R&#x000fc;tten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mentzel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Paredes</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Palmedo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panizzon</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Kutzner</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">23026936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kempf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kazakov</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Kutzner</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>May</month>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>809</fpage>
            <page-range>809-16</page-range>
            <pub-id pub-id-type="pmid">23375516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allabert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Est&#x000e8;ve</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Troussard</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Comoz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Courville</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verneuil</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leroy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dompmartin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Mucosal involvement in lymphomatoid papulosis: four cases].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>135</volume>
            <issue>4</issue>
            <fpage>273</fpage>
            <page-range>273-8</page-range>
            <pub-id pub-id-type="pmid">18420073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruijn</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Horv&#x000e1;th</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Voorst Vader</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group.</article-title>
            <source>Br J Dermatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>173</volume>
            <issue>5</issue>
            <fpage>1319</fpage>
            <page-range>1319-22</page-range>
            <pub-id pub-id-type="pmid">25998985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wieser</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Talpur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-67</page-range>
            <pub-id pub-id-type="pmid">26518172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miquel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamel-Teillac</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brousse</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>de Prost</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bodemer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Lymphomatoid papulosis in children: a series of 25 cases.</article-title>
            <source>Br J Dermatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>171</volume>
            <issue>5</issue>
            <fpage>1138</fpage>
            <page-range>1138-46</page-range>
            <pub-id pub-id-type="pmid">24749749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cordel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tressi&#x000e8;res</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>D'Incan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Est&#x000e8;ve</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Dalac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ingen-Housz-Oro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bagot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beylot-Barry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joly</surname>
                <given-names>P</given-names>
              </name>
              <collab>French Study Group on Cutaneous Lymphoma</collab>
            </person-group>
            <article-title>Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.</article-title>
            <source>Oncologist</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>76</fpage>
            <page-range>76-83</page-range>
            <pub-id pub-id-type="pmid">26668250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24603.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bekkenk</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Geelen</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>van Voorst Vader</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Heule</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Geerts</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>van Vloten</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Meijer</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Willemze</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.</article-title>
            <source>Blood</source>
            <year>2000</year>
            <month>Jun</month>
            <day>15</day>
            <volume>95</volume>
            <issue>12</issue>
            <fpage>3653</fpage>
            <page-range>3653-61</page-range>
            <pub-id pub-id-type="pmid">10845893</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
